News Archives - Page 2 of 3 - Evolution Biotechnologies
61
archive,paged,category,category-news,category-61,paged-2,category-paged-2,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

26 Feb

Posted at 11:38h in News by
0 Likes

Bedford, UK, February 23rd, 2019 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports that as a holder of the European Seal of Excellence for its work on house dust mite control, it has been selected to participate in the InvestEU Matchmaking event, to be held in Brussels, Belgium, on March 19th, 2019. The event involves discussions on sustainable finance and innovation, the Investment Plan for Europe, the InvestEU programme, and the Horizon 2020 and Horizon Europe programmes. After the discussions, attendees are invited to attend a dedicated matchmaking session with...

16 Jan

Posted at 09:22h in News by
0 Likes

Bedford, UK, January 9th, 2019 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports an interview with CEO Dr. David Harper, conducted by media company Proactive Investors during Biotech Showcase 2019. The interview covered the background to Evolution’s development of a novel, self-replicating control technology for house dust mites. Also covered were the recent granting of a European patent for this approach, and the company’s development plans. Dr. David Harper, Evolution’s CEO, said: “It is good to have the opportunity to speak to a wider audience about Evolution’s exciting developments in this...

10 Jan

Posted at 09:48h in News by
0 Likes

Bedford, UK, January 9th, 2019 Evolution (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today reports the announcement by the European Patent Office of notification of intention to grant Evolution’s patent EP3331366, “Acaricides”. The patent protects Evolution’s lead technology, developing a biological control for the house dust mite as a preventative for asthma. The patent provides broad protection for any use of replicating biological agents for the control of house dust mites (HDM). The first claim protects “A method of treating or preventing a house dust mite infestation, said method comprising applying an...

03 Jan

Posted at 13:02h in News by
0 Likes

Bedford, UK, October 3rd 2018 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control to benefit human health, today announced its intention to present at the Biotech Showcase in San Francisco. CEO Dr. David Harper will present a summary of the company’s activities, along with news of a major development on its key asthma control technology. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological...

18 Dec

Posted at 12:49h in News by
0 Likes

Bedford, UK, December 15th 2018 Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company pioneering the use of biological control in human disease, today announces the appointment of Mr. Edward C. Cappabianca as Chief Business Officer. Mr. Cappabianca has a strong background in investment banking, previously working with Alex. Brown & Sons, William Blair International, and Rodman & Renshaw, LLC. He also has operational management experience in the Biotech & Life Sciences sector having served as CEO of AmpliPhi Biosciences in the US and Founding CEO of EnXray in the UK. Mr. Cappabianca said “I am very pleased to join Evolution as a...

04 Oct

Posted at 10:16h in News by
0 Likes

Bedford, UK, 3 October 2018 ­Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced its intention to present at the LSX World Congress USA, to be held in Boston from 10 to 11 October, 2018. CEO, Dr. David Harper, will present a summary of the company’s activities, as well as an update on its current and planned development streams. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both...

16 May

Posted at 14:04h in News by
0 Likes

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced the publication of an invited paper written by Dr. David Harper, its Chief Executive Officer, as part of a special edition of the journal “Viruses”. The special edition is edited by Dr. Harald Brüssow and is focussed on “Hurdles for Phage Therapy (PT) to Become a Reality”. The paper, entitled “Criteria for Selecting Suitable Infectious Diseases for Phage Therapy” (Viruses 2018, 10(4), 177; https://doi.org/10.3390/v10040177) can be viewed at http://www.mdpi.com/1999-4915/10/4/177. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027) has been established to extend...

14 Nov

Posted at 13:19h in News by
0 Likes

Bedford, UK, November 14th 2017 ­Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced the highly positive outcome of the international (PCT) stage search and examination of its key patent filing PCT/GB2016/052455, “Acaricides”. The examination, conducted by the European Patent Office (EPO), confirmed the broad claim to a method of treating or preventing a house dust mite infestation using an acaricidal infectious agent as both novel and inventive. This is a key step towards obtaining broad protection for the work of the company in controlling house dust mites, a major...

14 Nov

Posted at 15:01h in News by
0 Likes

Bedford, UK, and Austin, Texas; November 14th 2016 Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announces the release of a video interview with its Chief Officer, Dr. David Harper, conducted by Dr. Robert Atterbury of Nottingham University. The interview forms part of the University’s online course on Antimicrobial Resistance in the Food Chain, which will launch on Monday 14th November: www.futurelearn.com/courses/antimicrobial-resistance-food-chain/. The interview can also be viewed by clicking on the following link  https://www.youtube.com/watch?v=DxKhlc4adKk. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application...

10 Nov

Posted at 11:45h in News by
0 Likes

Bedford, UK, and Austin, Texas; November 10th 2016 Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announces a presentation by its Chief Officer, Dr. David Harper. The presentation, entitled “Bacteriophage therapy – Still promising but not (yet) delivering" is to be given on Thursday 10th November via webex at the virtual conference held by Euroscicon on Developing antibiotic alternatives: A discussion of new approaches to overcoming antimicrobial resistance. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into...